Article by Nick Jikomes, Leafly
Insys Therapeutics, manufacturer of the synthetic opioid medication fentanyl, made headlines recently when it donated half a million dollars to the anti-cannabis legalization effort in Arizona. Fentanyl is a potent and highly addictive pain killer helping fuel the country’s opioid epidemic and skyrocketing overdose rates.
Presumably, Insys is funding anti-legalization efforts because legal cannabis represents a threat to its bottom line: medical cannabis can be an alternative to opioids for pain management, and states with medical marijuana laws are seeing lower rates of opioid abuse. In addition, there is evidence that plant cannabinoids such as cannabidiol (CBD) may be useful for treating opioid dependence. So it seems clear why a pharmaceutical company specializing in the sale of a synthetic opioid would oppose cannabis legalization.
But there’s more to it than that.
Insys is currently running a number of clinical trials investigating the use of cannabis-based therapies for a variety of ailments. If you go to ClinicalTrials.gov, a website run by the NIH, you can search through ongoing clinical trials in the U.S. based on disease, location, and who’s funding it. If you search “Insys,” a couple of things pop out: they’re running lots of trials to study fentanyl, and lots of trials to studycannabidiol (CBD).
CBD is non-psychoactive cannabinoid found in Cannabis, which we know is non-addictive and has wide-ranging therapeutic potential. Insys seems to know this as well, since they’re running CBD trials to treat everything from treatment-resistant child epilepsy to over-eating symptoms associated with Prader-Willi Syndrome (a rare genetic disorder). Search for, “Insys cannabidiol” on ClinicalTrials.gov and take a look for yourself.